GlassScriptPhysician profile
Paul B Donovan
NPI 1326003195
$6,801.96
in general payments reported to CMS, 2019-2025
38 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,803 · 2020: $715 · 2021: $1,025 · 2022: $763 · 2023: $437 · 2024: $557 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.91 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,664.12 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Amgen INC. | $717.56 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $591.16 | 2019-2022 | |
| Incyte Corporation | $461.36 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $261.57 | 2019-2024 | Darzalex, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $250.13 | 2022-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $248.48 | 2019-2025 | |
| Astellas Pharma US INC | $220.82 | 2019-2025 | Padcev |
| Celgene Corporation | $213.55 | 2019 | |
| Genzyme Corporation | $201.12 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.07 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $195.07 | 2019 | |
| Daiichi Sankyo INC. | $181.01 | 2019-2025 | Enhertu, Datroway |
| Pfizer INC. | $173.02 | 2019-2025 | |
| Abbvie INC. | $137.39 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.